Vascular Complications of Severe Hyperhomocysteinemia in Patients with Homocystinuria Due to Cystathionine β-Synthase Deficiency: Effects of Homocysteine-Lowering Therapy

ABSTRACT

Homocystinuria (HCU) due to cystathionine β-synthase (CBS) deficiency leads to severe hyperhomocysteinemia (HHcy). Vascular events (VE) remain the major cause of morbidity and mortality in the untreated patients with HCU. The study on the natural history of untreated HCU disclosed that, at the time of maximal risk, in other words beyond 10 years old, there was one event per 25 years. Recent studies from Australia (n = 32), The Netherlands (n = 28), and Ireland (n = 24) have documented the effects of long-term treatment on the vascular outcome of a total of 84 patients with 1314 patient-years of treatment for HCU. The mean (range) age was 27.8 (2.5 to 70) years. Five VE were recorded during treatment; one pulmonary embolism, two myocardial infarctions, and two abdominal aneurysms. All five VE occurred in B ₆-responsive patients at a mean (range) age of 48.8 (30 to 60) years. In 1314 patient-years of treatment, 53 VE would have been expected if they remained untreated; instead only 5 were documented, relative risk = 0.091 (95% confidence interval [CI] 0.043 to 0.190; p < 0.001). Appropriate homocysteine-lowering therapy for severe HHcy significantly reduced the vascular risk in patients with HCU. VE were rare with treatment despite the fact that the post-treatment homocysteine levels were several times higher than the cutoff point for homocysteine in the normal population. The present findings may have relevance to the current concept of ``mild HHcy'' as a risk factor for vascular disease, with elevated plasma homocysteine levels considerably lower than that of the post-treatment levels in this group of reported patients.

KEYWORD

Homocystinuria - cystathionine β-synthase deficiency - severe hyperhomocysteinemia - vascular complications - effects of treatment

REFERENCES

• 1 Perry T L. Homocystinuria. In: Nyan WL, ed. Heritable Disorders of Amino Acid Metabolism. New York: John Wiley, 1974: 395-428
• 2 Carson N AJ, Neill D W. Metabolic abnormalities detected in a survey of mental backward individuals in Northern Ireland.  Arch Dis Child . 1962;  37 505-513
• 3 Gerritsen T, Vaughn J G, Waisman H A. The identification of homocystine in the urine.  Biochem Biophys Res Commun . 1962;  9 493-496
• 4 Mudd S H, Levy H L, Skovby F. Disorders of transsulfuration. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease, 7th ed New York: McGraw-Hill, 1995: 1279-1327
• 5 Naughten E R, Yap S, Mayne P D. Newborn screening for homocystinuria: Irish and world experience.  Eur J Pediatr . 1998;  S84-87 (S84-87)
• 6 Barber G W, Spaeth G L. Pyridoxine therapy in homocystinuria.  Lancet . 1967;  1 337
• 7 Mudd S H, Skovby F, Levy H L. The natural history of homocystinuria due to cystathionine β-synthase deficiency.  Am J Hum Genet . 1985;  37 1-31
• 8 Kraus P J, Janosik M, Kozich V. Cystathionine β-synthase mutations in homocystinuria.  Hum Mutat . 1999;  13 362-375
• 9 Gallagher P M, Ward P, Soon T. High frequency of cystathionine β-synthase mutations G307S in Irish homocystinuria patients.  Hum Mutat . 1995;  6 177-180
• 10 Carson N AJ. Homocystinuria: Clinical and biochemical heterogeneity. In: Cockburn F, Gitzelmann R, eds. Inborn Errors of Metabolism in Humans Lancaster, England: MTP Press 1982: 53-67
• 11 Butz L W, du Vigneaud V. The formation of a homologue of cystine by the decompensation of methionine with sulfuric acid.  J Biol Chem . 1932;  99 135-142
• 12 Refsum H, Helland S, Ueland P M. Radioenzymic determination of homocysteine in plasma and urine.  Clin Chem . 1985;  31 624-628
• 13 Wiley V C, Dudman N PB, Wilcken D EL. Interrelations between plasma free and protein-bound homocysteine and cysteine in homocystinuria.  Metabolism . 1988;  37 191-195
• 14 Mudd S H, Levy H L. Plasma homocyst(e)ine or homocysteine?.  N Engl J Med . 1995;  333 325
• 15 Mansoor M A, Svardal A M, Schneede J, Veland P M. Dynamic relation between reduced, oxidised and protein bound homocysteine and other thiol components in plasma during methionine loading in healthy men.  Clin Chem . 1992;  38 1316-1321
• 16 Boers G HJ, Yap S, Naughten E, Wilcken B. The treatment of high homocysteine concentration in homocystinuria. Biochemical control in patients and their vascular outcome. In: Robinson K, ed. Homocysteine and Vascular Disease. Dordrecht, The Netherlands: Kluwer Academic Publishers, 2000: 387-409
• 17 Wilcken D EL, Wilcken B. The natural history of vascular disease in homocystinuria and the effects of treatment.  J Inher Metab Dis . 1997;  20 295-300
• 18 Kluijtmans L AJ, Boers G HJ, Kraus J P. The molecular basis of homocystinuria due to cystathionine β-synthase deficiency in Dutch homocystinuria patients. Effects of CBS genotype on biochemical and clinical phenotype, and on response upon treatment.  Am J Hum Genet . 1999;  65 59-67
• 19 Yap S, Naughten E. Homocystinuria due to cystathionine β-synthase deficiency in Ireland: 25 years' experience of a newborn screened and treated population with reference to clinical outcome and biochemical control.  J Inher Metab Dis . 1998;  21 738-747
• 20 Mayer E L, Jacobson D W, Robinson K. Homocysteine and coronary atherosclerosis.  J Am Coll Cardiol . 1996;  27 517-527
• 21 Motulsky A G. Nutritional ecogenetics: Homocysteine-related arteriosclerotic vascular disease, neural tube defects, and folic acid.  Am J Hum Genet . 1996;  58 17-20
• 22 Boushey C J, Beresford S AA, Omenn G S, Motulsky A G. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: Probable benefits of increasing folic acid intakes.  JAMA . 1995;  274 1049-1057
• 23 Mandel H, Brenner B, Berant M. Coexistence of hereditary homocystinuria and factor V Leiden-effects on thrombosis.  N Engl J Med . 1996;  334 763-768
• 24 Quere I, Lamarti H, Chadefaux-Vekemans B. Thrombophilia, homocystinuria and mutation of factor V gene.  N Engl J Med . 1996;  335 289
• 25 Kluijtmans L AJ, Boers G HJ, Verbruggen B. Homozygous cystathionine β-synthase deficiency, combined with factor V Leiden or thermolabile methylenetetrahydrofolate reductase in the risk of venous thrombosis.  Blood . 1998;  91 2015-2018
• 26 Yap S, O'Donnell K A, O'Neill C. Factor V Leiden (Arg506Gln), a confounding genetic risk factor but not mandatory for the occurrence of venous thromboembolism in homozygotes and obligate heterozygotes for cystathionine β-synthase deficiency.  Thromb Haemost . 1999;  81 502-505
• 27 Bertina R M, Koelman B PC, Berant M. Mutation in blood coagulation factor V associated with resistance to activated protein C.  Nature . 1994;  369 64-67
• 28 Seligsohn U, Zivelin A. Thrombophilia as a multigenic disorder.  Thromb Haemost . 1997;  78 297-301